Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows ...
Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.
Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can ...
Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...
An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...
Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.
Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...
Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...
In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...
Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback